down arrow

Finch Therapeutics Group, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US31773D2009
USD
13.62
0.17 (1.26%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

13.3514.75

52 Week

10.1516.10
Valuation
Technical
Day's Volume

CASH

9.78 k

Shareholding (Dec 2024)

FII

0.01%

Held by 2 FIIs

DII

97.75%

Held by 2 DIIs

Promoter

0.00%

What does Finch Therapeutics Group, Inc. do?

22-Jun-2025

Finch Therapeutics Group, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $21.84 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -158.08%.

Overview:<BR>Finch Therapeutics Group, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -5 Million (Quarterly Results - Jun 2024)<BR>Market cap: USD 21.84 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.98<BR>Return on Equity: -158.08%<BR>Price to Book: 2.41<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Read More

Is Finch Therapeutics Group, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Finch Therapeutics Group, Inc. to determine a bullish or bearish outlook.

As of 1 October 2023, the technical data for Finch Therapeutics Group, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Finch Therapeutics Group, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Finch Therapeutics Group, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2 and price-to-book ratio of 3.8, significantly exceeding those of its peers, indicating that investors are paying a premium without sufficient justification.

As of 5 October 2023, Finch Therapeutics Group, Inc. has moved from fair to overvalued. The company currently shows a price-to-earnings ratio of 45.2, a price-to-book ratio of 3.8, and a debt-to-equity ratio of 1.5. Compared to its peers, such as Seres Therapeutics with a price-to-earnings ratio of 12.5 and 4D Molecular Therapeutics with a price-to-book ratio of 2.1, Finch appears to be trading at a significant premium.<BR><BR>Given these metrics, Finch Therapeutics is considered overvalued. The elevated ratios indicate that investors are paying more for each dollar of earnings and book value compared to its peers, suggesting a lack of justification for its current market price. Additionally, while the stock has shown a positive return recently, it still does not align with the overall valuation metrics when compared to its industry counterparts.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 20 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.98

stock-summary
Return on Equity

-158.08%

stock-summary
Price to Book

2.19

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2024)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.1%
0%
8.1%
6 Months
0.15%
0%
0.15%
1 Year
12.28%
0%
12.28%
2 Years
203.34%
0%
203.34%
3 Years
1318.6%
0%
1318.6%
4 Years
-97.04%
0%
-97.04%
5 Years
0%
0%
0.0%

Finch Therapeutics Group, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
10.81%
EBIT to Interest (avg)
-48.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.88
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.28%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.40
EV to EBIT
-0.70
EV to EBITDA
-0.71
EV to Capital Employed
12.80
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1828.13%
ROE (Latest)
-158.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.25%)

Foreign Institutions

Held by 2 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 31.43% vs 69.16% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.10",
          "val2": "-9.00",
          "chgp": "32.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.80",
          "val2": "-7.00",
          "chgp": "31.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -88.89% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 81.42% vs 34.73% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.70",
          "val2": "-32.50",
          "chgp": "42.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-50.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.90",
          "val2": "-74.80",
          "chgp": "81.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-317,775.70%",
          "chgp": "31,777.57%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'24 - YoYstock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.10
-9.00
32.22%
Interest
0.00
0.00
Exceptional Items
0.00
-0.00
Consolidate Net Profit
-4.80
-7.00
31.43%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2024 is 31.43% vs 69.16% in Jun 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-18.70
-32.50
42.46%
Interest
0.00
0.00
Exceptional Items
-0.00
-50.50
100.00%
Consolidate Net Profit
-13.90
-74.80
81.42%
Operating Profit Margin (Excl OI)
0.00%
-317,775.70%
31,777.57%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -88.89% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 81.42% vs 34.73% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Finch Therapeutics Group, Inc. stock-summary
stock-summary
Finch Therapeutics Group, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."